Literature DB >> 15261143

The Sema domain of Met is necessary for receptor dimerization and activation.

Monica Kong-Beltran1, Jennifer Stamos, Dineli Wickramasinghe.   

Abstract

Hepatocyte growth factor (HGF) binds the extracellular domain and activates the Met receptor to induce mitogenesis, morphogenesis, and motility. The extracellular domain of Met is comprised of Sema, PSI, and four IPT subdomains. We investigated the contribution of these subdomains to Met receptor dimerization. Our observations indicate that the Sema domain is necessary for dimerization in addition to HGF binding. Treatment of Met-overexpressing tumor cells with recombinant Sema in the presence or absence of HGF results in decreased Met-mediated signal transduction, cell motility, and migration, behaving in a manner similar to an antagonistic anti-Met Fab. These data suggest that the Sema domain of Met may not only represent a novel anticancer therapeutic target but also acts as a biotherapeutic itself.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261143     DOI: 10.1016/j.ccr.2004.06.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  71 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 3.  Targeting the HGF/Met signaling pathway in cancer therapy.

Authors:  Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

4.  Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Authors:  Weiru Wang; Adhirai Marimuthu; James Tsai; Abhinav Kumar; Heike I Krupka; Chao Zhang; Ben Powell; Yoshihisa Suzuki; Hoa Nguyen; Maryam Tabrizizad; Catherine Luu; Brian L West
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

Review 5.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

Review 6.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 7.  Prognostic value of c-Met in colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Xiao-Feng Yu; Jian Zou; Zi-Hua Luo
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

8.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

9.  HGF and MET mutations in primary and secondary lymphedema.

Authors:  David N Finegold; Vivien Schacht; Mark A Kimak; Elizabeth C Lawrence; Etelka Foeldi; Jenny M Karlsson; Catherine J Baty; Robert E Ferrell
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

10.  Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.

Authors:  Mandy J Binning; Toba Niazi; Carolyn A Pedone; Bachchu Lal; Charles G Eberhart; K Jin Kim; John Laterra; Daniel W Fults
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.